HDT Bio Corp
Seattle, WA
- UEI
- Z33DCMWXZBK7
- CAGE
- 7YDE0
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1150 Eastlake Ave E #200a, Seattle, WA 98109, USA
- Website
- hdt.bio
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $129,000 |
| FY2024 | $0 |
| FY2023 | $749,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| IT1 Source LLC | 75N91025F00001 | $2,922,394 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Albert Einstein College Of Medicine | U19AI181977 | $1,962,637 | |
| University Of Washington | HT94252410649 | $108,479 | |
| Trustees Of Tufts College | R61AI197779 | $37,414 | |
| Fred Hutchinson Cancer Center | U19AI174242 | $691,918 | |
| Albert Einstein College Of Medicine | U19AI181977 | $2,000,327 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
HDT Bio Corp is a Seattle-based biopharmaceutical company specializing in developing innovative RNA-based vaccines, therapeutics, and drug delivery platforms. The company focuses on creating advanced medical solutions for infectious diseases, cancer, and other unmet medical needs, primarily working with self-replicating RNA (RepRNA) technologies and lipid inorganic nanoparticle (LION) delivery systems. Through its federal contract and grant awards, HDT Bio Corp provides research and development services to multiple federal agencies, with a particular emphasis on vaccine development, antiviral strategies, and advanced immunological technologies.
HDT Bio Corp has received federal contract awards primarily from agencies like the National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). These contracts have focused on developing rapid response vaccine technologies, such as a $749,000 contract for "Vaccine on Demand" research utilizing their Lion-ReRNA technology and a $1.5 million contract to develop an adaptable RNA-based antibody platform for protecting against contemporary and emerging human enteroviruses. The company has also received a significant $11 million contract to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein, through Phase I clinical trials. None of these contracts involved specific set-aside designations, and the work has been performed as definitive contracts with clear research and development objectives.
HDT Bio Corp's federal grant awards demonstrate a broad range of research initiatives across infectious diseases, vaccine development, and innovative medical technologies. The company has received grants from agencies including NIAID, the National Cancer Institute, and the Defense Health Agency. Notable grant projects include developing a muscle-localizing self-replicating RNA vaccine platform, creating a RIG-I agonist to prevent COVID-19, developing treatments for chronic hepatitis B, and engineering RNA vaccines for HIV-1. The company has also participated in sub-grant awards with prestigious institutions like Albert Einstein College of Medicine, University of Washington, and Tufts College, working on projects such as prepositioning vaccine strategies against emerging infectious threats, developing vaccines to prevent colorectal cancer, and exploring immune-based therapies. These grants typically range from small business innovation research (SBIR) Phase I awards to more comprehensive multi-year research projects, highlighting HDT Bio Corp's versatility and innovative approach to medical research.
Quick answers
Is HDT Bio Corp registered in SAM.gov?
Yes. HDT Bio Corp's SAM.gov registration is active through September 28, 2027.
How much has HDT Bio Corp received in federal contracts?
Federal contracts obligated $129,000 to HDT Bio Corp in fiscal year 2025 and $878,000 in fiscal years 2023 through 2027.
How does HDT Bio Corp rank among federal contractors?
HDT Bio Corp ranked #33 in PSC 3590 and #73 in PSC 35 in FY2025.
What is HDT Bio Corp's most recent federal award?
HDT Bio Corp's most recent federal contract award is Research service (N3239825PA019), from Bureau of Medicine and Surgery (Navy), on April 14, 2025.
On GovTribe
See HDT Bio Corp's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors